# Study of Erenumab (AMG 334) in Women With Hot Flashes

> **NCT01890109** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 103 (actual)

## Conditions studied

- Vasomotor Symptoms; Hot Flashes

## Interventions

- **BIOLOGICAL:** Erenumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01890109
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-13
- **Primary completion:** 2014-03-11
- **Final completion:** 2014-03-11
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2019-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01890109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01890109, "Study of Erenumab (AMG 334) in Women With Hot Flashes". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01890109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*